Drug Eluting Balloons Catheters Market Valued At $2.92 Billion In 2026: Key Trends And Growth Drivers
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Drug Eluting Balloons Catheters Market Size, Value And Growth Trajectory Through 2030
The drug eluting balloons catheters market size has seen rapid growth in recent years. This market is expected to increase from $1.65 billion in 2025 to $1.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.5%. The expansion witnessed during the historic period is due to factors such as the rising incidence of coronary artery disease, the increasing adoption of percutaneous coronary interventions, advancements in balloon catheter materials, the clinical acceptance of paclitaxel-coated devices, and the proliferation of interventional cardiology centers.
The drug eluting balloons catheters market size is anticipated to undergo substantial growth in the forthcoming years. It is projected to expand to $2.92 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This expansion throughout the forecast period stems from the escalating demand for minimally invasive vascular therapies, the increasing embrace of sirolimus-based balloons, the broadening array of peripheral vascular disease treatments, rising investments in next-generation catheter technologies, and a greater emphasis on long-term patient outcomes. Significant developments foreseen in this period encompass the growing adoption of drug-coated balloon technologies, their increased utilization in coronary and peripheral interventions, an evolving preference for stent-free treatment options, the advancement of sophisticated drug coating techniques, and a sharpened focus on preventing restenosis.
Get A Free Sample Report With In-Depth Market Insights:
Drug Eluting Balloons Catheters Market Growth Backed By Core Demand Fundamentals
The increasing occurrence of peripheral and cardiovascular ailments is projected to drive expansion in the drug-eluting balloon catheter market in the future. Cardiovascular diseases (CVDs) encompass various conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) is characterized by constricted arteries limiting blood flow mainly to the limbs. Drug-eluting balloon catheters offer a therapeutic approach for coronary artery disease (CAD), utilizing a semi-compliant angioplasty balloon covered with an anti-proliferative agent, designed to exert an anti-restenotic impact upon insertion into a blood vessel. A notable example is data from January 2024, where the American Heart Association, a US-based non-profit organization, reported that the age-adjusted cardiovascular disease mortality rate climbed to 233.3 deaths per 100,000 in 2024, representing a 4.0% year-on-year increase from 224.4 deaths per 100,000 in 2023. Consequently, the rising incidence of peripheral and cardiovascular conditions is fueling the drug-eluting balloon catheter market.
Drug Eluting Balloons Catheters Market Segment Landscape And Growth Outlook
The drug eluting balloons catheters market covered in this report is segmented –
1) By Product: Coronary Artery Disease, Peripheral Vascular Disease, Drug-Eluting Balloon Catheters
2) By Drug: Paclitaxel, Sirolimus, Other Drugs
3) By Raw Material: Nylon, Polyurethane, Other Raw Materials
4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories
Subsegments:
1) By Coronary Artery Disease: Coronary Drug-Eluting Balloon Catheters, Coronary In-Stent Restenosis Drug-Eluting Balloon Catheters, Coronary Small-Vessel Drug-Eluting Balloon Catheters
2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Femoro-Popliteal Drug-Eluting Balloon Catheters, Below-the-Knee (BTK) Drug-Eluting Balloon Catheters
3) By Drug-Eluting Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters
Drug Eluting Balloons Catheters Market Growth Trends Reshaping The Competitive Landscape
Key players within the drug-eluting balloon catheter market are intensifying their efforts to create cutting-edge, next-generation products incorporating sophisticated technologies, aiming to secure a competitive advantage. For example, in March 2024, Boston Scientific Corporation, a US-based biomedical/biotechnology engineering and medical device manufacturing multinational, declared that its AGENT Drug-Coated Balloon (DCB) had received approval from the U.S. Food and Drug Administration (FDA). The AGENT DCB represents the first drug-coated coronary balloon available in the U.S. designed to address in-stent restenosis (ISR), a condition characterized by plaque or scar tissue obstructing a vessel that has been stented. This device incorporates a paclitaxel coating which delivers a therapeutic dosage directly to the vessel wall, thereby lowering the chances of ISR recurring without requiring further stents or radiation therapy. Clinical studies demonstrated a 49% decrease in heart attack risk at the treated location and indicated minimal occurrences of adverse events.
Drug Eluting Balloons Catheters Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the drug eluting balloons catheters market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB
View The Full Drug Eluting Balloons Catheters Market Report:
Drug Eluting Balloons Catheters Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the drug eluting balloons catheters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
